Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2013 03:30 ET | Source: Pluri Inc.

Preclinical Research Shows PLX Cells May be Effective in Treating Preeclampsia

HAIFA, Israel, May 13, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today its PLacental eXpanded...
May 07, 2013 03:00 ET | Source: Pluri Inc.

Pluristem Develops PLX-RAD Cells for Use in Hematology

HAIFA, Israel, May 7, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that it has identified its...
April 30, 2013 03:00 ET | Source: Pluri Inc.

Pluristem to Present at Needham Healthcare and Oppenheimer Israeli Investment Conferences in May 2013

HAIFA, Israel, April 30, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today the company is scheduled...
April 29, 2013 03:00 ET | Source: Pluri Inc.

Third Party Research Study Demonstrates Pluristem's PLX-PAD Cells' Safety in Human Lung Models of Pulmonary Hypertension

HAIFA, Israel, April 29, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that independent...
April 18, 2013 03:00 ET | Source: Pluri Inc.

Pluristem Expands PLX Product Portfolio in Orthopedics and Sports Medicine

HAIFA, Israel, April 18, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today it is expanding its...
April 11, 2013 03:00 ET | Source: Pluri Inc.

United Therapeutics Receives Regulatory Approval to Commence Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension

HAIFA, Israel, April 11, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that following favorable...
April 10, 2013 02:00 ET | Source: Pluri Inc.

Pluristem Announces Scientific and Investment Conferences for April 2013

HAIFA, Israel, April 10, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today the Company is scheduled...
March 20, 2013 03:00 ET | Source: Pluri Inc.

Pluristem Reports on the Progress of Its Phase I/II Clinical Trial for the Treatment of Muscle Injury

HAIFA, Israel, March 20, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today reported on the progress of its...
February 26, 2013 09:00 ET | Source: Pluri Inc.

United Therapeutics Moves Forward Towards a Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension

HAIFA, Israel, Feb. 26, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that following favorable...
February 21, 2013 02:30 ET | Source: Pluri Inc.

Pluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic Anemia

HAIFA, Israel, Feb. 21, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the U.S. Food and...